Jurgen Figys
Overview
When pharma and biotech companies are in need of cross-jurisdictional intellectual property/patent and regulatory advice, they trust Jurgen Figys for his understanding of the life sciences business — being trained as a biomedical scientist and seconded at pharma companies — as well as his profound knowledge of the legal IP and regulatory challenges in this field. As one of the few lawyers in Belgium also trained as a scientist, Jurgen is able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field.
Career & Education
- Free University of Brussels (Vrije Universiteit Brussel), M.B.M.S., magna cum laude, 2001
- Free University of Brussels (Vrije Universiteit Brussel), LL.M., cum laude, 2010
- Belgium
- Dutch
- English
- French
Jurgen Figys, who benefits from a background in biomedical science, is routinely sought out by a host of companies for his extensive experience]in regulatory issues, SPC (supplementary protection certifications) litigation and digital transformation in the healthcare sector.
— Legal 500, 2022
Jurgen's Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Firm News | 2 min read | 06.06.24
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Firm News | 3 min read | 04.01.24
Recognition
- IAM 1000: Gold – Firms: Litigation and Transactions, 2024
Jurgen's Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Firm News | 2 min read | 06.06.24
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Firm News | 3 min read | 04.01.24
Insights
Counterfeit Seizures Proceedings in Belgium – An Update
|08.29.17
Cahiers Antwerp Brussels Ghent
Jouer avec les limites de l'usage off-label?
|02.13.15
Le Journal du Médecin 2394, 39
De Minimis in Belgian Patent Law
|01.01.15
I.R.D.I.
De exclusieve bevoegdheid van de rechtbank van koophandel en het hof van beroep te Brussel in het nieuwe Wetboek intellectuele eigendom (Boek XI van het WER)
|12.26.14
RABG
Practices
- Intellectual Property — Brussels Practice
- Life Sciences — Brussels Practice
- Dispute Resolution — Brussels Practice
- Intellectual Property Litigation
- Litigation and Trial
- Regulatory — Brussels Practice
- Intellectual Property
- European IP Law
- Patent Litigation
- Copyright — Brussels Practice
- Trademarks and Designs — Brussels Practice
- Health Care
- Digital Health and Health Information Technology
Industries
Jurgen's Insights
Client Alert | 5 min read | 06.24.24
The Judgment of the Brussels Court of Appeal is the latest development in the saga in Belgium where a Belgian parallel importer, PI Pharma NV, imported a generic Sandoz product from the Netherlands, repackaged and rebranded them, and placed them on the Belgian market alleging they were a Novartis’ originator product.
Firm News | 2 min read | 06.06.24
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Firm News | 3 min read | 04.01.24